hCG Treatment for Rehabilitation From a TBI
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Madison, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 50 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ovidrel
- Placebo
- Record updated
- 19 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Subject is 1-month but < 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the time of screening (Visit 1)
- Stable doses of any medication, supplement or medical food that may affect brain function, unless deemed medically necessary by the patient's physician for optimal healthcare
- Fluent in English
- Reasonable expectation of availability to receive the 24-week course of therapy and be available for follow up evaluations
Who cannot take part
- Receiving other investigational drugs within 30 d or 5 half-lives prior to randomization, whichever longer
- Taking human chorionic gonadotropin (hCG), or any condition known to elevate human chorionic gonadotropin (hCG), active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor
- Patients with evidence of an active or previous thrombotic event
- Renal disease; Asthma; known endocrine or germ cell tumor
- Presence of significant systemic illness likely to interfere with participation in or completion of the study or to affect study results
- History of deep venous thrombosis (DVT) or venous thromboembolism (VTE)
- History of sleep apnea
- Patients with known hypercoagulability, including cardiolipin/antiphospholipid antibody syndrome
- Allergy or other contraindication to human chorionic gonadotropin (hCG)
- Uncontrolled hypertension, defined as blood pressure persistently above 140 mm Hg systolic or 95 mm Hg diastolic despite antihypertensive therapy
- History of breast or prostate cancer; sex hormone dependent tumors of the reproductive organs or accessory sex glands
- Patients who have 6 or more symptoms for substance use disorder according to DSM-5 criteria
- Taking other medications known to affect serum sex hormone or gonadotropin concentrations such as testosterone for hormone replacement therapy, goserelin or danazol, in the past three (3) months
- Significantly depressed (Geriatric Depression Scale > 10)
- Patients considered to be at risk for suicidality or homicidality according to the Columbia Suicide Severity Rating Scale (CSSRS)
- Primary hypogonadism (unrelated to trauma)
- Male patients with known/documented elevated PSA levels, or a PSA level of 4ng/mL at screening
- Clinically significant peripheral edema
- Severe symptoms of benign prostatic hyperplasia (BPH), i.e., International Prostate Symptom Score greater than or equal to 20 points
- Uncontrolled thyroid, adrenal or pituitary dysfunction
- An uncontrolled organic intracranial lesion such as a pituitary tumor
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- William S. Middleton Memorial Veterans Hospital, Madison, WIMadison, United StatesContact: Jenna W Quinto, PhDNot yet recruiting
About the trial
What the trial wants to find out
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
The 2 groups in the trial
- Treatment ArmTreatment being tested
Ovidrel: 125 micrograms in 0.25 milliliters (mL) administered subcutaneously twice weekly for 24 weeks
Treatment: Ovidrel
- Placebo ArmPlacebo, for comparison
Placebo: 0.25 milliliters (mL) of sterile normal saline administered subcutaneously twice weekly for 24 weeks
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Chorionic Gonadotropin to Improve Rehabilitation After Brain Injury - The COGNI-REHAB Study
- Criteria questions
- Built from NCT07557615, who can take part
- Record updated
- 19 October 2026